1Centre for Technology Enabled Health Research, Coventry University, Coventry, UK
2McMaster University, Hamilton, Ontario, Canada
3Kaiser Permanente, Oakland, California, USA
4Leicester General Hospital, Leicester, UK
5Case Western Reserve University School of Medicine, Case and VA Medical Center Cleveland, Cleveland, Ohio, USA
6University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
7University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
8NHS Foundation Trust, Warwick, UK
9Klinikum Bayreuth, Bayreuth, Germany
10University of Washington School of Medicine, Seattle, Washington, USA
11Worcestershire Acute Hospitals NHS Trust, Redditch, UK
12National University Health System, Singapore, Singapore
13Brigham and Women's Hospital, Boston, Massachusetts, USA
14Johns Hopkins School of Medicine, Baltimore, Maryland, USA
15Weill Cornell Medical College and Houston Methodist Hospital, Houston, Texas, USA
16ECD Solutions, Columbus, Ohio, USA
17Queen’s University, Belfast, UK
18Imperial College, St Mary’s Hospital, London, UK
19Mayo Clinic, Rochester, Minnesota, USA
20Norwich Medical School, University of East Anglia, Norwich, UK
21University of Manchester, Manchester, UK
22Department of Gastroenterology, University Hospital Southampton, Southampton, UK
24Lyell McEwin Hospital/University of Adelaide, Adelaide, South Australia, Australia
25Queen Alexandra Hospital, Portsmouth, UK
26University Hospitals Leuven, Leuven, Belgium
27Department of Pathology, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
28Nottingham University Hospitals NHS Trust, Nottingham, UK
29Gastrointestinal Oncology Research Group, AMC, Amsterdam, The Netherlands
30Oregon Health and Science University, Portland, Oregon, USA
31Department of Gastroenterology HSK Wiesbaden, Wiesbaden, Germany
32University of Pittsburgh, Pittsburgh, Pennsylvania, USA
33Krankenhaus Barmherzige Brueder, Regensburg, Germany
34University of Chicago, Chicago, Illinois, USA
35Queens Medical Centre, University of Nottingham, Nottingham, UK
36University Hospital Southampton, Southampton, UK
38University of Arizona Cancer Center, Tucson, Arizona, USA
39University Medical Center Utrecht, Utrecht, The Netherlands
40University of Leuven, Leuven, Belgium
41Ulster Hospital, Belfast, Northern Ireland, UK
42Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK
43Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
44Washington University School of Medicine, Saint Louis, Missouri, USA
46Yong Loo Lin School of Medicine, National University of Singapore, Singapore
47Durham University, Durham, UK
48Otto-Von-Guericke-Universität Magdeburg, Magdeburg, Germany
49University of British Columbia, Vancouver, British Columbia, Canada
50Gloucestershire Royal Hospital, Gloucester, UK
51The University of Chicago Medicine, Chicago, Illinois, USA
52University Hospitals Coventry and Warwickshire and University of Warwick, Coventry, UK
Correspondence: J Jankowski, MD, PhD, Translational and Systems Medicine, Clinical Sciences Research Laboratories, Clinical Sciences Building, University Hospitals of Coventry and Warwickshire, University of Warwick, Coventry CV2 2DX, UK. E-mail: [email protected]
53Equal rank first.
SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/AJG/B78
Received 01 December 2014; accepted 03 February 2015
Guarantor of the article: Janusz Jankowski, MD, PhD.
Specific author contributions: Stuart Gittens: ECD solutions, designed the web-based consensus system (received consultancy fee). Cathy Bennett and Stuart Gittens administered the voting processes and provided reports of voting results. Yngve Falck-Ytter and Cathy Bennett carried out the GRADE assessments. BOB CAT authors contributed to at least four project development domains, including evidence review and statement development, analysis and conception of project, in addition to voting, commenting, and paper writing (except C.B. and S.G. who did not vote). The BOB CAT Consortium contributed to at least one of the project development domains, in addition to voting and commenting. All authors approved the final draft. Project development domains: (i) conception of the project; (ii) methodological advice; (iii) analysis of data; (iv) writing the paper; (v) evidence review; (vi) question formulation and statement development; (vii) voting and commenting; and (viii) attending meetings.
Financial support: We thank the following organizations who supported us financially and/or endorsed the process. None of these organizations influenced in any way the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. In alphabetical order: American College of Gastroenterology (AGC) (endorsement only); American Gastroenterology Association (AGA) (endorsement and $2,500); Association of Upper GI Surgeons (AUGIS) (endorsement and £1,000); British Society of Gastroenterology (BSG) (endorsement and £4,000); Canadian Association of Gastroenterology (CAG) (endorsement only); Deutsche Gesellschaft fìr Verdauungs und Stoffwechselkrankheiten (DGVS) (endorsement and €1,000; European Society of Thoracic Surgeons (ESTS) (endorsement only); Fight Oesophageal Reflux Together (FORT); (endorsement and £4,000), German Gastroenterology Society (DGG) (endorsement and €1,000); International Society of Diseases of the Esophagus (ISDE) (endorsement, $5,000, and support for meetings and teleconferences); International Working Group for Columnar Esophagus (IWGCE) (endorsement only); Oesophageal Charity Fund of Ireland (OCF) (endorsement and €6,000), World Gastroenterology Organisation (endorsement only). Plymouth University, UK, provided essential core support. Dr Katie Nason was funded by the NCI/NIH Award Number K07CA511613. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Potential competing interests: Participants who do not appear here declare no conflict of interest. William Allum: receipt of honoraria from Lilly, Nestle, and Astellas Oncology. David Armstrong: received consulting, educational, and research funding from AstraZeneca, Aptalis, Abbvie, Covidien, Eisai, Forest Laboratories, Janssen, Negma, and Takeda (incl. Nycomed). Hugh Barr: chief investigator of the Barretts oesophagus surveillance study (BOSS) funded by the NIHR UK. Also the principal investigator for the AspECT trial. He offers advice to the NICE National Institute for Clinical Excellence, and have consulted for AXCANPHARMA and AstraZeneca. Cathy Bennett: coordinator of BOB CAT and received a consultancy fee. Member of the data monitoring committee for the BOSS clinical trial (scheduled vs. at need surveillance endoscopy in BE). Proprietor of Systematic Research, a consultancy company, and derives an income from this. Raf Bisschops: Barrx Medical (Covedien): speaker’s fee and consultancy; Olympus: speaker’s fee; Fujifilm: speaker’s fee; Pentax: speaker’s fee. Douglas Corley: research funding provided by Pfizer. Gary Falk: consultant for Olympus and CDX. Grant Fullarton: has received consultancy fees on two occasions for attending Barryx and subsequently Covidien meetings regarding RFA for BE. Stuart Gittens: received a consultancy fee for developing the BOB CAT website. Nalini Guda: consultant for Boston Scientific. Christine Hachem: registry participant for Halo Covidien registry. Michio Hongo: Astra Zeneca, and Daiichi-Sankyo, Eisai, Astellas Pharma, Zeria Pharmaceutical, Dainippon-Sumitomo Pharma. John Inadomi: given imaging: Advisory Board ChemImage: Clinical Advisory Committee Cernostics (BE molecular markers): Scientific Advisory Board Epigenomics (BE Diagnostics): scientific advisory board. Janusz Jankowski: was consultant to AstraZeneca from 2002 to 2012 (maker of a proton pump inhibitor). Chief Investigator of the aspirin chemoprevention trial, AspECT. Chief Investigator of the EAGLe genomics consortia. Vani Konda: Mauna Kea Technologies Olympus. Peter Malfertheiner: research support and lecture honoraria from Aptalis, AZ, Fuji, Takeda. Hiroto Miwa: receives consultant fee from Astra Zeneca, Takeda Pharmaceutical. Helmut Neumann: consultant for Pentax, Mauna Kea Technologies, and Spectra Science; speaker fee from Essex Pharma, Abbott, Pentax, Mauna Kea Technologies, Eisai; research grants from Pentax, Siemens, Olympus, Nycomed, AstraZeneca, Pfizer. Praful Patel: hospitality, Covidien. Oliver Pech: speaker’s honorarium for Covidien, Fujifilm, Falk, Norgine. Eamonn Quigley: advisory boards: Salix, Janssen, Rhythm, Ironwood/Forest, Shire/Movetis, Vibrant. Research support: Alimentary Health, Rhythm, Vibrant. Krish Ragunath: received research support, educational grants, and speaker honoraria from Olympus Keymed, Cook Medical, and BARRX Medical. Jaroslaw Regula: has received travel support from Olympus and speakers fee from Krka, Polpharma, and Takeda. Prateek Sharma: grant support from Cook Medical, Olympus, Ninepoint Medical, Takeda, CDx Diagnostics. George Triadafilopoulos: equity position: C2 Therapeutics Research support: Covidien. Kenneth Wang: funding from Ninepoints, Covidien for research Advisory board CDX. Peter Watson: on TMG AspECT trial.
